Comment on "Preclinical assessment of the neutralizing capacity of antivenoms produced in six Latin American countries against medically-relevant Bothrops snake venoms"

Toxicon

Volumn 57, Issue 7-8, 2011, Pages 1109-1110

  Dias da Silva, Wilmar ^a   Tambourgi, Denise V ^a  

^a INSTITUTO BUTANTAN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

SEPHAROSE; SNAKE VENOM ANTISERUM;

AFFINITY CHROMATOGRAPHY; ANTIGENICITY; ARGENTINA; BOLIVIA; BOTHROPS ASPER; BOTHROPS ATROX; BOTHROPS JARARACA; BOTHROPS NEUWIEDII; BRAZIL; COLOMBIA; COSTA RICA; DRUG SPECIFICITY; ION EXCHANGE CHROMATOGRAPHY; LETTER; NONHUMAN; PERU; PRIORITY JOURNAL; SNAKE; SPECIES COMPARISON;

ANIMALS; ANTIVENINS; BOTHROPS; COMMUNICATION; DRUG EVALUATION, PRECLINICAL; LATIN AMERICA; NEUTRALIZATION TESTS; SNAKE VENOMS; SPECIES SPECIFICITY;

BOTHROPS;

EID: 79956341468     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2011.03.022     Document Type: Letter

References (3)

1. Guidolin R.G., Marcelino R.M., Gondo H.G., Morais J.F., Ferreira R., Silva C.L., Kipnis T.L., Silva J.A., Fafetine J., Dias da Silva W. Polyvalent horse F(ab')2 snake antivenom: development of process to produce polyvalent horse F(Ab')2 antibodies anti-African snake venom. Afr. J. Biotechnol. 2010, 9:2446-2455.
2. Raw I., Higashi H.G., Kelen E.M. Antivenom production and organization of the public health system for the treatment of envenoming in Brazil. Envenomings and Their Treatments 1996, Foundation Marcel Mérieux, Lyon, France. C. bon, M. Goyffon (Eds.).
3. Segura A., Castillo M.C., Núñez V., Yarlequé A., Gonçalves L.R., Villalta M., Bonilla C., Herrera M., Vargas M., Fernández M., Yano M.Y., Araújo H.P., Boller M.A., León P., Tintaya B., Sano-Martins I.S., Gómez A., Fernández G.P., Geoghegan P., Higashi H.G., León G., Gutiérrez J.M. Preclinical assessment of the neutralizing capacity of antivenoms produced in six Latin American countries against medically-relevant Bothrops snake venoms. Toxicon 2010, 56:980-989.